Skip to main content
Clinical Trials/NCT06068426
NCT06068426
Completed
Not Applicable

Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management

David Vitale MD1 site in 1 country66 target enrollmentSeptember 13, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Pancreatitis
Sponsor
David Vitale MD
Enrollment
66
Locations
1
Primary Endpoint
EUS Pancreatic Findings- Rosemont Criteria
Status
Completed
Last Updated
9 months ago

Overview

Brief Summary

The main reason for this research study is to find out more about acute recurrent pancreatitis and chronic pancreatitis in children. There are few studies on childhood pancreatitis, so diagnosis and treatment are based on adult studies. This limits our understanding and treatment of these disorders in children.

Endoscopic ultrasound (EUS) is a tool used to assess and diagnose pancreatic disease. We can use ultrasound with shear wave elastography (SWE) to measure fibrosis (scarring) of the pancreas. We can use SWE on both EUS and transabdominal ultrasound (TUS) systems. Both TUS and EUS SWE have been studied for diagnosis of chronic pancreatitis in adult patients, however they have not been studied in children.

We plan to use EUS SWE and TUS SWE information in this study to help us understand pancreatitis in children. Children with pancreatitis and children without pancreatitis (controls) will be invited to participate in this study.

Detailed Description

The aims of the proposed study are as follows: Aim 1: Characterize endoscopic ultrasound (EUS) findings of pediatric acute recurrent pancreatitis (ARP) and chronic pancreatitis (CP). Adult criteria for EUS diagnosis of CP exist, but no such criteria exist for children. As such, the applicability of current diagnostic criteria to pediatric patients is unknown. 1.1: Catalogue grayscale EUS findings of ARP and CP in a pediatric cohort and compare to healthy controls. Hypothesis: EUS findings of ARP and CP in pediatric patients will differ from those of adult ARP and CP and will be characteristically different from healthy controls. Exp1: We will catalogue grayscale EUS findings in 40 pediatric patients with known history of ARP or CP undergoing clinically indicated EUS and will compare those with findings in 20 patients without a history of pancreatitis who are undergoing EUS for other indications. 1.2: Benchmark grayscale EUS against other imaging modalities for diagnosis of CP, particularly early CP, in children. Hypothesis: Grayscale EUS findings will be more sensitive than other imaging modalities in all stages of CP. Exp2: We will test associations, in blinded fashion, of grayscale EUS findings catalogued under S.A1.1 in enrolled children with findings on alternative pancreas imaging modalities performed for clinical indications. Specifically, we will correlate to endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP) and computed tomography (CT) performed for clinical indications within +/- 3 months of the EUS. Aim 2: Define the diagnostic performance of ultrasound elastography for CP and pancreatic stiffness as a measure of fibrosis in pediatric patients. 2.1: Define the diagnostic performance of EUS and TUS elastography for pediatric CP. Hypothesis: EUS and TUS elastography will have high specificity for CP with increased stiffness in patients compared to controls. Exp 1: Patients enrolled under Aim 1 will undergo shear wave elastography (SWE) measurement of the pancreas during EUS. These same patients will undergo research TUS with SWE of the pancreas. SWE results by both EUS and TUS will be evaluated for diagnostic performance for CP. 2.2: Define agreement between EUS and TUS measurement of pancreatic parenchymal stiffness in pediatric patients. Hypothesis: EUS and TUS measures of pancreatic parenchymal stiffness will agree with minimal bias. Exp2: EUS and TUS SWE data obtained under S.A2.1 will be evaluated for agreement and divergent cases will be investigated to define causes. 2.3: Define the diagnostic performance of elastography for pancreatic fibrosis. Hypothesis: SWE is a sensitive indicator of pancreatic fibrosis as identified by histology. Exp3: Patients undergoing clinically indicated total pancreatectomy and islet auto transplant (TPIAT) or other pancreatic surgical resection at our institution (approximately 20 per year) will be approached to undergo pre-operative TUS SWE. These SWE measurements, along with EUS SWE measurements obtained preoperatively, will be compared to binary and semi-quantitative assessments of pancreatic parenchymal fibrosis by histology.

Registry
clinicaltrials.gov
Start Date
September 13, 2021
End Date
August 4, 2023
Last Updated
9 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
David Vitale MD
Responsible Party
Sponsor Investigator
Principal Investigator

David Vitale MD

Assistant Professor

Children's Hospital Medical Center, Cincinnati

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

EUS Pancreatic Findings- Rosemont Criteria

Time Frame: At time of EUS procedure

Rosemont Criteria Features * Hyperechoic foci with shadowing (Major A) * Lobularity with honeycombing (Major B) * Lobularity without honeycombing (Minor) * Hyperechoic foci without shadowing (Minor) * Cysts (Minor) * Stranding (Minor) * Main pancreatic duct calculi (Major A) * Irregular main pancreatic duct contour (Minor) * Dilated side branches (Minor) * Main pancreatic duct dilation (Minor) * Hyperechoic main pancreatic duct margin (Minor)

Secondary Outcomes

  • Acute Recurrent Pancreatitis(6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound))
  • Diabetes Mellitus(6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound))
  • Calculated BMI(6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound))
  • Chronic Pancreatitis(6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound))
  • Exocrine Pancreatic Insufficiency(6 months (3 months prior to endoscopic ultrasound through 3 months post-endoscopic ultrasound))
  • MRI Cambridge Grade: Mild(At time of MRI)
  • ERCP Cambridge Criteria: Mild(At time of ERCP)
  • EUS Rosemont Classification - Normal(At time of EUS)
  • EUS Rosemont Classification - Suggestive of CP(At time of EUS)
  • EUS Rosemont Classification - Indeterminate for CP(At time of EUS)
  • MRI Cambridge Grade: Normal(At time of MRI)
  • EUS Rosemont Classification - Consistent With CP(At time of EUS)
  • ERCP Cambridge Criteria: Equivocal(At time of ERCP)
  • MRI Cambridge Grade: Equivocal(At time of MRI)
  • MRI Cambridge Grade: Moderate(At time of MRI)
  • MRI Cambridge Grade: Severe(At time of MRI)
  • ERCP Cambridge Criteria: Normal(At time of ERCP)
  • ERCP Cambridge Criteria: Moderate(At time of ERCP)
  • ERCP Cambridge Criteria: Marked(At time of ERCP)

Study Sites (1)

Loading locations...

Similar Trials